Clinical Trials Logo

Adenocarcinoma of Lung clinical trials

View clinical trials related to Adenocarcinoma of Lung.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06441357 Recruiting - Clinical trials for Adenocarcinoma of Lung

Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter

Start date: June 1, 2024
Phase:
Study type: Observational

The core purpose of this study is to investigate whether the extracellular volume (ECV) fraction measured in delay phase by dual energy computed tomography (DECT) can distinguish precancerous lesions from early-stage lung adenocarcinomas, which could assist clinical decision making for surgery operation indication and strategy.

NCT ID: NCT06387134 Recruiting - Clinical trials for Early Stage Lung Adenocarcinoma

Lifei Xiaoji Wan Treatment's of Early-stage NSCLC and Its Impact on the Tumor Microenvironment

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

This study evaluated the relationship between the clinical efficacy, histopathological changes and tumor microenvironment of the pharmacopharmacologic Lifei Xiaoji Wan in the treatment of early stage lung adenocarcinoma, and improved high-level clinical evidence and action targets for the prevention and treatment of early stage lung cancer by traditional Chinese medicine

NCT ID: NCT06299163 Recruiting - Endometrial Cancer Clinical Trials

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

Start date: May 1, 2024
Phase: Phase 1
Study type: Interventional

This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.

NCT ID: NCT06255197 Recruiting - Lung Cancer Clinical Trials

Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers

Start date: November 4, 2019
Phase:
Study type: Observational

This study is a multi-center, observational, real-world study for patients with resected lung cancers in China. With the help of a properly designed data processing algorithm and extensively performed data quality assurance, this study aims to harness the potential of real-world big data to (1) describe characteristics and treatment patterns and their evolving trends; (2) discover features associated with overall survival; and (3) address recently-emerging clinical questions.

NCT ID: NCT06181812 Recruiting - Lung Adenocarcinoma Clinical Trials

Pathogenic Variants in Genes Associated With Lung Adenocarcinoma

Start date: December 15, 2022
Phase:
Study type: Observational

The goal of this observational study is to describe the prevalence of germ line-pathogenic variants in Mexican patients with lung adenocarcinoma. The main questions it aims to answer are: 1. What is the prevalence of pathogenic variants in genes associated with lung adenocarcinoma in Mexican patients younger than fifty? 2. Which clinical-pathological characteristics are associated with germ-line pathogenic variants in patients with lung adenocarcinoma? 3. How actionable somatic mutations are associated with germ line-pathogenic variants of patients with lung adenocarcinoma? Participants will be asked to sign an informed consent; after that, they will be instructed to donate 10 ml of peripheral blood by venipuncture in the morning and before the patient has taken morning medication and the first meal, following a period of 8-12 hr fasting.

NCT ID: NCT06056115 Recruiting - Lung Adenocarcinoma Clinical Trials

Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

Brain metastasis of lung cancer is one of the most important metastasis pathways in patients with life-threatening diseases. This study explore the efficacy and safety of Tislelizumab combining with platinum-containing drug chemotherapy in the first-line treatment of Lung Adenocarcinoma With Asymptomatic Brain Metastatic. Meanwhile, Related biomarkers were explored to provide theoretical basis for efficacy evaluation and resistance mechanism.

NCT ID: NCT06031246 Recruiting - Lung Adenocarcinoma Clinical Trials

Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)

Start date: April 1, 2023
Phase: Phase 3
Study type: Interventional

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1018. The goal of this clinical trial is to confirm the theraputic effect of selective lymph node dissection for cT1N0M0 invasive non-small cell lung cancer with CTR>0.5 located in the apical segment. The main questions it aims to answer are: The 5-year overall survival of patients having cT1N0M0 invasive non-small cell lung cancer with CTR>0.5 located in the apical segment; The post-operative lymph node metastasis and recurrence-free survival. Participants will receive selective lymph node dissection as the surgical procedure.

NCT ID: NCT06031181 Recruiting - Lung Adenocarcinoma Clinical Trials

Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)

Start date: March 31, 2023
Phase: Phase 3
Study type: Interventional

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1019. The goal of this clinical trial is to confirm the therapeutic effect of sublobar resection for AIS/MIA diagnosed by intraoperative frozen section.

NCT ID: NCT05943795 Recruiting - Clinical trials for Squamous Cell Carcinoma of Lung

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Start date: July 14, 2023
Phase: Phase 3
Study type: Interventional

Main objectives: To evaluate the benefit of SI-B001+ docetaxel on overall survival (OS) of bidotaxel. To evaluate the benefit of SI-B001+ Docetaxel over Docetaxel's progression-free survival (PFS) based assessment. Secondary objectives: To evaluate the investigator-evaluated progression-free survival (PFS) benefit of SI-B001+ Docetaxel against docetaxel; To evaluate the difference of objective response rate (ORR), disease control rate (DCR) and duration of response (DOR) between SI-B001+ docetaxel and bidocetaxel. To evaluate the type, frequency and severity of adverse events (TEAE) and drug-related adverse events (TRAE) during treatment with SI-B001+ docetaxel in comparison with docetaxel. The pharmacokinetic (PK) characteristics of SI-B001 will be evaluated. The immunogenicity of SI-B001 will be evaluated. Subject quality of life.

NCT ID: NCT05925764 Recruiting - Lung Adenocarcinoma Clinical Trials

Whole Slide Image for Predicting the Novel Grading System of Resected Lung Adenocarcinoma

Start date: May 1, 2023
Phase:
Study type: Observational

The purpose of this study is to evaluate the performance of a whole slide image based deep learning signature for predicting the novel grading system in resected lung adenocarcinoma based on a multicenter prospective cohort.